Subscribe to RSS
DOI: 10.1055/a-2460-8999
Wilson Disease: Novel Diagnostic and Therapeutic Approaches
Abstract
The Wilson disease (WD) research field is rapidly evolving, and new diagnostic and therapeutical approaches are expected to be change-gamers in the disease for the incoming years, after decades of slow changing options. Non–ceruloplasmin-bound copper assays for circulating bioavailable copper are being tested for use in monitoring therapy and may also help in the diagnosis of new cases of WD. Other diagnostic advances include the use of quantitative detection of ATP7B peptides in dried blood spots, a method that is being tested for use in the newborn screening for WD, and the use of metallothionein immunostaining of liver biopsy specimens to differentiate WD from other liver diseases. Ongoing and future trials of gene therapy and use of methanobactin are expected to restore biliary copper excretion from the liver, thus making a cure for WD a plausible therapeutic objective. With the aim of helping updating physicians, this review summarizes the novel methods for WD diagnosis and future therapies. Advancing understanding of the scientific advances that can be applied to WD will be critical for ensuring that our patients will receive the best current and future care.
Disclosures
• Z.M.: Speaker fees from Gilead and Orphalan; consultancy fees from Alexion, DeepGenomics, and Orphalan; grants from Gilead.
• M.L.S.: Grants from Vivet Therapeutics, Orphalan, Alexion, Wilson Disease Association, National Institute of Health; consultant to DepYmed, Arbomed, Orphalan.
Publication History
Accepted Manuscript online:
04 November 2024
Article published online:
26 November 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Schilsky ML, Roberts EA, Bronstein JM. et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology 2022 ; ( online ahead of print)
- 2 Roberts EA, Schilsky ML. Current and emerging issues in Wilson's disease. N Engl J Med 2023; 389 (10) 922-938
- 3 Zimbrean PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. Gen Hosp Psychiatry 2014; 36 (01) 53-62
- 4 Ferenci P, Caca K, Loudianos G. et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int 2003; 23 (03) 139-142
- 5 European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56 (03) 671-685
- 6 Socha P, Janczyk W, Dhawan A. et al. Wilson's disease in children: a position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018; 66 (02) 334-344
- 7 El Balkhi S, Poupon J, Trocello JM. et al. Determination of ultrafiltrable and exchangeable copper in plasma: stability and reference values in healthy subjects. Anal Bioanal Chem 2009; 394 (05) 1477-1484
- 8 El Balkhi S, Trocello JM, Poupon J. et al. Relative exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson's disease diagnosis. Clin Chim Acta 2011; 412 (23-24): 2254-2260
- 9 El Balkhi S, Trocello JM, Poupon J. et al. Relative exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson's disease diagnosis. Liver Int 2012; 44 (01) 192-200
- 10 Poujois A, Trocello JM, Djebrani-Oussedik N. et al. Exchangeable copper: a reflection of the neurological severity in Wilson's disease. Eur J Neurol 2017; 24 (01) 154-160
- 11 Guillaud O, Brunet AS, Mallet I. et al. Relative exchangeable copper: a valuable tool for the diagnosis of Wilson disease. Liver Int 2018; 38 (02) 350-357
- 12 Mariño Z, Molera-Busoms C, Badenas C. et al. Benefits of using exchangeable copper and the ratio of exchangeable copper in a real-world cohort of patients with Wilson disease. J Inherit Metab Dis 2023; 46 (05) 982-991
- 13 Ngwanou DH, Couchonnal E, Parant F. et al. Long-term urinary copper excretion and exchangeable copper in children with Wilson disease under chelation therapy. J Pediatr Gastroenterol Nutr 2022; 75 (04) e75-e80
- 14 Jacquelet E, Poujois A, Pheulpin MC. et al. Adherence to treatment, a challenge even in treatable metabolic rare diseases: a cross sectional study of Wilson's disease. J Inherit Metab Dis 2021; 44 (06) 1481-1488
- 15 Trocello JM, El Balkhi S, Woimant F. et al. Relative exchangeable copper: a promising tool for family screening in Wilson disease. Mov Disord 2014; 29 (04) 558-562
- 16 Solovyev N, Ala A, Schilsky M, Mills C, Willis K, Harrington CF. Biomedical copper speciation in relation to Wilson's disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry. Anal Chim Acta 2020; 1098: 27-36
- 17 Del Castillo Busto ME, Cuello-Nunez S, Ward-Deitrich C, Morley T, Goenaga-Infante H. A fit-for-purpose copper speciation method for the determination of exchangeable copper relevant to Wilson's disease. Anal Bioanal Chem 2022; 414 (01) 561-573
- 18 Schilsky ML, Czlonkowska A, Zuin M. et al; CHELATE Trial Investigators. Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol 2022; 7 (12) 1092-1102
- 19 Bitzer AC, Fox J, Day PL. et al. Establishment of a labile bound copper reference interval in a healthy population via an inductively coupled plasma mass spectrometry dual filtration-based assay. Arch Pathol Lab Med 2024; 148 (07) 818-827
- 20 Harrington CF, Carpenter G, Coverdale JPC. et al. Accurate non-ceruloplasmin bound copper: a new biomarker for the assessment and monitoring of Wilson disease patients using HPLC coupled to ICP-MS/MS. Clin Chem Lab Med 2024; ; ( online ahead of print)
- 21 Sandahl TD, Harrington CF, Carpenter G. et al. Accurate non-ceruloplasmin copper as a diagnostic test for Wilson disease in acute liver failure. Hepatology 2023; 78 (S1): S1482 (3300-A)
- 22 Ott P, Sandahl T, Ala A. et al. Non-ceruloplasmin copper and urinary copper in clinically stable Wilson disease: alignment with recommended targets. JHEP Rep Innov Hepatol 2024; 6 (08) 101115
- 23 Collins CJ, Yi F, Dayuha R. et al. Direct measurement of ATP7B peptides is highly effective in the diagnosis of Wilson disease. Gastroenterology 2021; 160 (07) 2367-2382.e1
- 24 Ferenci P, Steindl-Munda P, Vogel W. et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson's disease. Clin Gastroenterol Hepatol 2005; 3 (08) 811-818
- 25 Yang X, Tang XP, Zhang YH. et al. Prospective evaluation of the diagnostic accuracy of hepatic copper content, as determined using the entire core of a liver biopsy sample. Hepatology 2015; 62 (06) 1731-1741
- 26 Gerosa C, Fanni D, Congiu T. et al. Liver pathology in Wilson's disease: from copper overload to cirrhosis. J Inorg Biochem 2019; 193: 106-111
- 27 Danscher G, Zimmer J. Histochemistry an improved timm sulphide silver method for light and electron microscopic localization of heavy metals in biological tissues. Histochemistry 1978;55
- 28 Mulder TP, Janssens AR, Verspaget HW, van Hattum J, Lamers CB. Metallothionein concentration in the liver of patients with Wilson's disease, primary biliary cirrhosis, and liver metastasis of colorectal cancer. J Hepatol 1992; 16 (03) 346-350
- 29 Rowan DJ, Mangalaparthi KK, Singh S. et al. Metallothionein immunohistochemistry has high sensitivity and specificity for detection of Wilson disease. Mod Pathol 2022; 35 (07) 946-955
- 30 Wiethoff H, Mohr I, Fichtner A. et al. Metallothionein: a game changer in histopathological diagnosis of Wilson disease. Histopathology 2023; 83 (06) 936-948
- 31 Schilsky ML, Blank RR, Czaja MJ. et al. Hepatocellular copper toxicity and its attenuation by zinc. J Clin Invest 1989; 84 (05) 1562-1568
- 32 Członkowska A, Rodo M, Wierzchowska-Ciok A, Smolinski L, Litwin T. Accuracy of the radioactive copper incorporation test in the diagnosis of Wilson disease. Liver Int 2018; 38 (10) 1860-1866
- 33 Sandahl TD, Gormsen LC, Kjærgaard K. et al. The pathophysiology of Wilson's disease visualized: a human 64Cu PET study. Hepatology 2022; 75 (06) 1461-1470
- 34 Espinós C, Ferenci P. Are the new genetic tools for diagnosis of Wilson disease helpful in clinical practice?. JHEP Rep Innov Hepatol 2020; 2 (04) 100114
- 35 Weiss KH, Thurik F, Gotthardt DN. et al; EUROWILSON Consortium. Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 2013; 11 (08) 1028-35.e1 , 2
- 36 Munk DE, Lund Laursen T, Teicher Kirk F. et al. Effect of oral zinc regimens on human hepatic copper content: a randomized intervention study. Sci Rep 2022; 12 (01) 14714
- 37 Kirk FT, Munk DE, Swenson ES. et al. Effects of trientine and penicillamine on intestinal copper uptake: a mechanistic 64 Cu PET/CT study in healthy humans. Hepatology 2024; 79 (05) 1065-1074
- 38 Siegemund R, Lössner J, Günther K, Kühn HJ, Bachmann H. Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson's disease. Acta Neurol Scand 1991; 83 (06) 364-366
- 39 Irato P, Sturniolo GC, Giacon G. et al. Effect of zinc supplementation on metallothionein, copper, and zinc concentration in various tissues of copper-loaded rats. Biol Trace Elem Res 1996; 51 (01) 87-96
- 40 Camarata MA, Ala A, Schilsky ML. Zinc maintenance therapy for Wilson disease: a comparison between zinc acetate and alternative zinc preparations. Hepatol Commun 2019; 3 (08) 1151-1158
- 41 Weiss KH, Gotthardt DN, Klemm D. et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 2011; 140 (04) 1189-119 8.e1.
- 42 Center for Drug Evaluation and Research. FDA-Approval Package for Galzin [cited August 25, 2024]. . (Includes Study conducted by Brewer G. “The Efficacy and Safety of Zinc Acetate as Maintenance Therapy of Wilson's Disease”) Accessed November 11, 2024 at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020458ap.pdf
- 43 Walshe JM. Management of penicillamine nephropathy in Wilson's disease: a new chelating agent. Lancet 1969; 2 (7635) 1401-1402
- 44 Weiss KH, Thompson C, Dogterom P. et al. Comparison of the pharmacokinetic profiles of trientine tetrahydrochloride and trientine dihydrochloride in healthy subjects. Eur J Drug Metab Pharmacokinet 2021; 46 (05) 665-675
- 45 Weiss KH, Kruse C, Manolaki N. et al. Multicentre, retrospective study to assess long-term outcomes of chelator based treatment with trientine in Wilson disease patients withdrawn from therapy with d -penicillamine. Eur J Gastroenterol Hepatol 2022; 34 (09) 940-947
- 46 Mohr I, Bourhis H, Woimant F. et al. Experience on switching trientine formulations in Wilson disease: efficacy and safety after initiation of TETA 4HCl as substitute for TETA 2HCl. J Gastroenterol Hepatol 2023; 38 (02) 219-224
- 47 Ala A, Aliu E, Schilsky ML. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease. Dig Dis Sci 2015; 60 (05) 1433-1439
- 48 Summer KH, Lichtmannegger J, Bandow N, Choi DW, DiSpirito AA, Michalke B. The biogenic methanobactin is an effective chelator for copper in a rat model for Wilson disease. J Trace Elem Med Biol 2011; 25 (01) 36-41
- 49 Balasubramanian R, Rosenzweig AC. Copper methanobactin: a molecule whose time has come. Curr Opin Chem Biol 2008; 12 (02) 245-249
- 50 Medici V, Huster D. Animal Models of Wilson disease. In: Handbook of Clinical Neurology. Elsevier B.V.; 2017: 57-70
- 51 Einer C, Munk DE, Park E. et al. ARBM101 (methanobactin SB2) drains excess liver copper via biliary excretion in Wilson's disease rats. Gastroenterology 2023; 165 (01) 187-200.e7
- 52 Malhi H, Irani AN, Volenberg I, Schilsky ML, Gupta S. Early cell transplantation in LEC rats modeling Wilson's disease eliminates hepatic copper with reversal of liver disease. Gastroenterology 2002; 122 (02) 438-447
- 53 Roybal JL, Endo M, Radu A. et al. Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson's disease. Gene Ther 2012; 19 (11) 1085-1094
- 54 Murillo O, Luqui DM, Gazquez C. et al. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. J Hepatol 2016; 64 (02) 419-426
- 55 Murillo O, Moreno D, Gazquez C. et al. Liver expression of a MiniATP7B gene results in long-term restoration of copper homeostasis in a Wilson disease model in mice. Hepatology 2019; 70 (01) 108-126
- 56 Murillo O, Collantes M, Gazquez C. et al. High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease. Mol Ther Methods Clin Dev 2022; 26: 98-106
- 57 Sandahl TD, Lee WM, Ala A. et al. WED-164 - Interim safety results of the ongoing international phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson disease. J Hepatol 2024; 80 :(Suppl 1) doi:
- 58 Weiss KH, Askari FK, Czlonkowska A. et al. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2017; 2 (12) 869-876
- 59 Brewer GJ, Hedera P, Kluin KJ. et al. Treatment of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60 (03) 379-385
- 60 Brewer GJ, Askari F, Dick RB. et al. Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 2009; 154 (02) 70-77
- 61 Weiss KH, Schilsky M, Czlonkowska A. et al. Efficacy and safety of ALXN1840 versus standard of care in Wilson disease: primary results from an ongoing phase 3, randomized, controlled, rater-blinded trial. O01- International Liver Meeting 2022. Gut 2022; 71 (Suppl. 03) A1-A96
- 62 Komatsu Y, Sadakata I, Ogra Y, Suzuki KT. Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats. Chem Biol Interact 2000; 124 (03) 217-231
- 63 Kirk FT, Munk DE, Swenson ES. et al. Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease. J Hepatol 2024; 80 (04) 586-595